Background {#Sec1}
==========

Patient outcomes among critically ill patients are significantly affected by occurrences of pain, agitation, and delirium (PAD). For instance, delirium, a fluctuating disturbance in attention and awareness, has been estimated to occur in up to 80% of mechanically ventilated patients and has been associated with increased cost, length of stay, duration of mechanical ventilation, and mortality, as well as long-term cognitive impairment \[[@CR1]--[@CR4]\]. Given this scope and significance, past and present guidelines have recommended strategies for preventing and treating pain, agitation, and delirium \[[@CR1], [@CR5]\]. Guidelines published in 2013 by the Society of Critical Care Medicine include recommendations for adequate analgesia, lighter sedation, performance of spontaneous awakening trials (i.e., daily cessation of sedation and reassessment of sedation needs), and preferential use of non-benzodiazepine sedatives.

Despite evidence supporting guideline recommendations, however, it is unclear how fully and quickly recommendations have been adopted into practice. To date, limited surveys of practitioners and institutions have revealed delayed and incomplete adoption of guidelines along with inflated perceptions of adherence to guidelines and best practices. \[[@CR6]--[@CR10]\].

The objectives of this study were first to characterize trends in pain and sedation strategies over time and across world regions using actual patient care data and second to identify aspects of clinical practice associated with occurrence of delirium in critically ill patients. We hypothesized that practice would vary significantly between year and region and that delirium would be less frequent in 2016 than in 2010.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

We performed a retrospective analysis of a multicenter, international, institutional review board (IRB)-approved, prospective cohort study. Data were acquired from the third (March 2010) and fourth (July 2016) International Studies of Mechanical Ventilation (ISMV), which occurred before and after publication of the 2013 PAD guidelines. Conducted every 6 years since 1998, the ISMV primarily investigates the impact of ventilation practices on mortality. Over the course of 1 month, clinical data were collected prospectively on mechanically ventilated patients until discharge, death, or 28 days after admission. The first three ISMV studies have been described previously \[[@CR11]--[@CR13]\], and the fourth ISMV cohort is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT02731898).

Included patients in the fourth ISMV cohort must have been admitted to an intensive care unit (ICU) requiring invasive mechanical ventilation (endotracheal tube or tracheostomy) for longer than 12 h or non-invasive mechanical ventilation (bilevel positive airway pressure \[BIPAP\] or continuous positive airway pressure \[CPAP\]) for more than 1 h or have been transferred to a participating ICU after already receiving mechanical ventilation. Patients less than 18 years of age and those admitted after elective surgery requiring less than 12 h of invasive mechanical ventilation were excluded.

Measurements and outcomes {#Sec4}
-------------------------

Our outcomes were twofold. First, we analyzed how analgesia and sedation strategies varied across years and regions, including proportion of patient days receiving analgesics and sedatives, choice of sedatives, and performance of spontaneous awakening trials (SATs). Second, we investigated how occurrence of delirium varied by year and region.

Daily use of analgesia and sedation were defined in the ISMV as an infusion utilized for longer than three consecutive hours and are herein described as proportion of total patient days with sedation (referred to as a sedation day) or analgesia. Use of sedative agents are further described as proportion of sedation days receiving each agent. Performance of SATs are described as the proportion of sedation days incorporating a cessation of sedation.

The features of inattentiveness, disorganized thinking, and altered consciousness were employed as general protocol definition for delirium. However, countries participating in this cohort could have used any delirium tool. In addition, level of sedation using Richmond Agitation and Sedation Scale (RASS) was required to be between − 3 and + 4 for a delirium classification (ISMV 4 only; RASS not collected in ISMV 3). Additional collected variables included age, gender, body mass index (BMI), simplified acute physiology score (SAPSII), international region, reason for ventilation, choice of sedative and analgesic, performance of an SAT, use of neuromuscular blockage (NMB), and RASS (ISMV 4 only). Measurements were performed on a daily basis per ISMV study protocol.

Statistical analysis {#Sec5}
--------------------

Cohorts from 2010 and 2016 were compared overall and for each region. Median and interquartile range (IQR) are presented for continuous variables, while count and proportion (*n*, %) are presented for categorical variables. For clinical practice (e.g., sedation use), differences in proportion of days were calculated and weighted individual proportions were used to calculate standard errors and *p* values to account for varying length of stay and data points for each patient. Pearson's chi-squared test was used to compare prevalence of delirium. In addition, a multinomial regression model was used to investigate associations of various risk factors with daily development of delirium or coma with normal (i.e., no delirium, no coma) as reference in the 2016 cohort. Model covariates included baseline variables (age, gender, BMI, SAPS II, region), previous day clinical variables (use of propofol, use of benzodiazepines, use of dexmedetomidine, use of analgesia, use of neuromuscular blockers), performance of spontaneous awakening trial, and day of admission.

Statistical analyses were performed using IBM SPSS Statistics Version 24.0 (Armonk, NY: IBM Corp) and statistical software R version 3.3.0 (R Development Core Team Vienna, Austria; <https://www.r-project.org/>), considering *p* \< 0.05 to indicate statistical significance.

Results {#Sec6}
=======

This study evaluated analgesia and sedation practices in 14,281 patients in 6 international regions before and after publication of 2013 PAD guidelines. Demographics were similar between 2010 and 2016 (Table [1](#Tab1){ref-type="table"}) with median ages of 63 and 64 years, respectively, and SAPS II scores of 45 and 44, correlating to an estimated hospital mortality of approximately 35% \[[@CR14]\]. Europe was the most represented region with approximately 40% of patients, followed by Latin America (22% in 2010, 26% in 2016), and Asia (17% in 2010, 26% in 2016). The United States (US) and Canada combined region contributed 11% and 5% of patients in 2010 and 2016, respectively. The most common reason for mechanical ventilation was a postoperative status (22% in 2010, 23% in 2016). Sepsis and pneumonia were each the reason for mechanical ventilation in approximately 10% of patients in each year. In addition, there were no differences in length of stay (5 vs. 4 days) or duration of mechanical ventilation (4 days) between groups (2010 vs. 2016).Table 1Baseline demographics2010\
*n* = 73232016\
*n* = 6958Age63 (49--74)64 (50--75)Male4571 (62%)4347 (62%)BMI25.5 (22.9--28.9)25.1 (22.6--28.3)SAPSII45 (33--58)44 (32--58)Region USA/Canada825 (11.3%)322 (4.6%) Europe2931 (40.0%)2677 (38.5%) Africa133 (1.8%)169 (2.4%) Asia1226 (16.7%)1816 (26.1%) Latin America1576 (21.5%)1809 (26.0%) Australia/New Zealand632 (8.6%)165 (2.4%)Reason for ventilation COPD exacerbation336 (4.6%)323 (4.6%) Asthma80 (1.1%)44 (0.6%) Other chronic pulmonary disease87 (1.2%)116 (1.7%)Coma^a^ Metabolic265 (3.8%)287 (4.4%) Overdose/intoxication211 (3.0%)197 (3.0%) Hemorrhagic stroke470 (6.7%)434 (6.6%) Ischemic stroke214 (3.1%)199 (3.0%) Brain trauma302 (4.3%)378 (5.7%)Neuromuscular disease74 (1.0%)93 (1.4%)Acute respiratory failure ARDS256 (3.5%)284 (4.1%) Postoperative1702 (23.2%)1538 (22.1%) CHF399 (5.4%)346 (5.0%) Aspiration188 (2.6%)167 (2.4%) Pneumonia697 (9.5%)737 (10.6%) Sepsis715 (9.8%)700 (10.6%) Trauma347 (4.7%)296 (4.3%) Cardiac arrest473 (6.8%)443 (6.7%) Other ARF400 (5.5%)261 (3.8%)Continuous variables reported as median (IQR). Categorical variables reported as *n* (%)^a^Coma subtype was missing in 341 and 384 patients in 2010 and 2016, respectivelyDefinitions of abbreviations: *ARDS* acute respiratory distress syndrome, *ARF* acute respiratory failure, *CHF* congestive heart failure, *BMI* body mass index, *SAPS* simplified acute physiology score

The use of analgesia and sedation varied between study years and regions. From 2010 to 2016, the proportion of patient days with opioid infusions increased from 45 to 62% (*p* \< 0.001), and the proportion of patient days with sedative infusions (i.e., sedation days) increased from 47 to 58% (*p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). Similar increases were seen in all regions.Table 2Proportion of days utilizing analgesia and sedation20102016Difference (95% CI)*p* valueAnalgesia Overall23,854/52803 (45%)25,017/40612 (62%)0.164 (0.160 to 0.168)\< 0.001 Europe11,472/22005 (52%)10,931/15592 (70%)0.180 (0.173 to 0.187)\< 0.001 US/Canada2142/4984 (43%)1054/1993 (53%)0.099 (0.083 to 0.115)\< 0.001 Asia3033/9335 (32%)4398/10096 (44%)0.111 (0.103 to 0.119)\< 0.001 Africa254/869 (29%)499/912 (55%)0.255 (0.224 to 0.286)\< 0.001 Australia/New Zealand1579/3094 (51%)533/672 (79%)0.283 (0.259 to 0.307)\< 0.001 Latin America5374/12516 (43%)7602/11347 (67%)0.241 (0.233 to 0.249)\< 0.001Sedation Overall24,925/52803 (47%)23,520/40612 (58%)0.107 (0.102 to 0.112)\< 0.001 Europe11,773/22005 (54%)10,468/15592 (67%)0.136 (0.129 to 0.143)\< 0.001 US/Canada2439/4984 (49%)1030/1993 (52%)0.027 (0.008 to 0.046)0.003 Asia3401/9335 (36%)4507/10096 (45%)0.082 (0.073 to 0.091)\< 0.001 Africa281/869 (32%)500/912 (55%)0.225 (0.192 to 0.258)\< 0.001 Australia/New Zealand2016/3094 (65%)577/672 (86%)0.207 (0.183 to 0.231)\< 0.001 Latin America5015/12516 (40%)6438/11347 (57%)0.167 (0.158 to 0.176)\< 0.001

The choice of sedative varied between years and regions, as well (Table [3](#Tab3){ref-type="table"}). In 2010, benzodiazepines were the most frequently used sedative in all regions with use being highest in Africa and Latin America (95% of sedation days). From 2010 to 2016, the use of any benzodiazepine decreased from 71 to 55% of sedation days overall (*p* \< 0.001). Africa experienced the least change in choice of sedative between 2010 and 2016. Overall, the use of propofol increased from 38 to 41% of sedation days from 2010 to 2016 (*p* \< 0.001). By 2016, propofol had become the most frequently used sedative in the US/Canada, Europe, and Australia/New Zealand, while Africa, Latin America, and Asia still utilized benzodiazepines most frequently. In addition, propofol was nearly twice as common in Australia and New Zealand in 2010 compared to other regions. Use of dexmedetomidine increased from 0.8 to 11% overall (*p* \< 0.001), with Asia using it most frequently in 2016 (29% of sedation days).Table 3Proportion of days using sedative agentsBenzodiazepines Overall17,627/24925 (71%)12,955/23520 (55%)− 0.156 (− 0.16 to − 0.152)\< 0.001 Europe7178/11773 (61%)4939/10468 (47%)− 0.138 (− 0.145 to − 0.131)\< 0.001 US/Canada1803/2439 (74%)372/1030 (36%)− 0.378 (− 0.397 to − 0.359)\< 0.001 Asia2725/3401 (80%)2093/4507 (46%)− 0.337 (− 0.346 to − 0.328)\< 0.001 Africa267/281 (95%)448/500 (90%)− 0.054 (− 0.069 to − 0.039)\< 0.001 Australia/New Zealand887/2016 (44%)122/577 (21%)− 0.229 (− 0.255 to − 0.203)\< 0.001 Latin America4767/5015 (95%)4981/6438 (77%)− 0.177 (− 0.183 to − 0.171)\< 0.001Propofol Overall9526/24925 (38%)9728/23520 (41%)0.031 (0.027 to 0.035)\< 0.001 Europe6012/11773 (51%)6095/10468 (58%)0.072 (0.064 to 0.08)\< 0.001 US/Canada829/2439 (34%)672/1030 (65%)0.313 (0.294 to 0.332)\< 0.001 Asia876/3401 (26%)1380/4507 (31%)0.049 (0.039 to 0.059)\< 0.001 Africa15/281 (5%)34/500 (7%)0.015 (0.002 to 0.028)0.023 Australia/New Zealand1545/2016 (77%)496/577 (86%)0.093 (0.069 to 0.117)\< 0.001 Latin America249/5015 (5%)1051/6438 (16%)0.114 (0.108 to 0.12)\< 0.001Dexmedetomidine Overall196/24925 (0.8%)2615/23520 (11%)0.103 (0.101 to 0.105)\< 0.001 Europe24/11773 (0.2%)609/10468 (6%)0.056 (0.053 to 0.059)\< 0.001 US/Canada5/2439 (0.2%)84/1030 (8%)0.08 (0.068 to 0.092)\< 0.001 Asia14/3401 (0.4%)1309/4507 (29%)0.286 (0.28 to 0.292)\< 0.001 Africa0/281 (0%)0/500 (0%)---- Australia/New Zealand32/2016 (1.6%)59/577 (10%)0.086 (0.07 to 0.102)\< 0.001 Latin America121/5015 (2.4%)554/6438 (9%)0.062 (0.057 to 0.067)\< 0.001Proportion of days using each sedative out of the total days when any sedation was received

Between 2010 and 2016, the performance of SATs increased from 20 to 21% of sedation days (*p* \< 0.001). The overall increase was driven by the US/Canada which saw performance of SATs increase from 24 to 35% of sedation days (*p* \< 0.001). SAT performance increased modestly in Europe from 15 to 18% (*p* \< 0.001), stayed relatively flat in Asia, Latin America, and Australia/New Zealand, and decreased in Africa (*p* \< 0.001) (Table [4](#Tab4){ref-type="table"}).Table 4Proportion of days utilizing spontaneous awakening trials20102016Difference (95% CI)*p* valueOverall4848/24925 (20%)4963/23520 (21%)0.017 (0.013 to 0.021)\< 0.001Europe1771/11773 (15%)1892/10468 (18%)0.03 (0.023 to 0.037)\< 0.001US/Canada589/2439 (24%)356/1030 (35%)0.104 (0.082 to 0.126)\< 0.001Asia1017/3401 (30%)1361/4507 (30%)0.003 (− 0.006 to 0.012)0.521Africa92/281 (33%)77/500 (15%)− 0.173 (− 0.198 to − 0.148)\< 0.001Australia/New Zealand446/2016 (22%)120/577 (21%)− 0.013 (− 0.042 to 0.016)0.360Latin America933/5015 (19%)1157/6438 (18%)− 0.006 (− 0.015 to 0.003)0.165Proportion of days with SAT performed out of the total days when any sedation was received

As shown in Table [5](#Tab5){ref-type="table"}, any occurrence of delirium during admission increased from 7% of patients in 2010 to 9% of patients in 2016 (*p* = 0.007), driven by the US/Canada region, which saw delirium rates double between 2010 and 2016 (17% vs. 36%, *p* \< 0.001). Occurrence of delirium also increased in Latin America (5% vs. 10%, *p* \< 0.001). There were no significant changes in Europe (6% vs. 6%, *p* = 0.964), Asia (6% vs. 7%, *p* = 0.152), Africa (1% vs. 0%, *p* = 0.440), or Australia/New Zealand (13% vs. 8%, *p* = 0.098).Table 5Prevalence of delirium during admission20102016*p* valueOverall542/7323 (7%)600/6958 (9%)0.007Europe182/2931 (6%)167/2677 (6%)0.964US/Canada136/825 (17%)115/322 (36%)\< 0.001Asia71/1226 (6%)129/1816 (7%)0.152Africa1/133 (1%)0/169 (0%)0.440Australia/New Zealand79/632 (13%)13/165 (8%)0.098Latin America73/1576 (5%)176/1809 (10%)\< 0.001

Multinomial analysis was consistent with previous literature identifying benzodiazepine use with increased development of delirium and dexmedetomidine use with decreased development of delirium. Full results are shown in the Additional file [1](#MOESM1){ref-type="media"}

Discussion {#Sec7}
==========

As hypothesized, the degree of implementation of recommended sedation strategies varied dramatically by region. In accordance with guideline recommendations, use of analgesia increased, performance of SATs increased, and use of benzodiazepines decreased. However, opportunities for improvement include minimizing overall sedation, continuing to decrease benzodiazepine use, and increasing performance of SATs. Contrary to our hypothesis, occurrence of delirium did not change or increased from 2010 to 2016.

Use of non-benzodiazepine sedatives has been associated with decreased ICU length of stay, increased ventilator free days, and decreased incidence of delirium \[[@CR15]--[@CR18]\]. Likewise, performance of daily SATs has been shown to reduce duration of mechanical ventilation and decrease rates of post-traumatic stress disorder after an ICU admission \[[@CR19], [@CR20]\]. Bundling such guideline-based practices during ICU admission has recently been shown to decrease mortality \[[@CR21]--[@CR23]\]. Differences in benzodiazepine use between regions may reflect resource constraints, as benzodiazepines cost substantially less than propofol and dexmedetomidine. However, use of non-benzodiazepines and lighter sedation strategies may be cost-effective overall due to improvement in patient outcomes and decreased overall resource utilization \[[@CR24]\].

The observed increase in delirium from 2010 to 2016, especially in the US/Canada region may be due to observation bias as awareness and training for identifying delirium increase. The single-digit rates seen in this study conflict with previous estimates of delirium occurring in up to 80% of mechanically ventilated patients \[[@CR2]\]. Daily delirium assessment using a validated tool was protocolized, and only a small percentage of data were missing, but it is possible that assessment and documentation of delirium were inconsistent between years, regions, and sites. This highlights the need for education and training for accurate assessment of delirium in clinical practice and studies and to engage in consistent delirium monitoring.

Our study has several strengths. Most notably, this is the first study to our knowledge to assess guideline implementation using actual clinical practice throughout admission. Our findings confirm that implementation of guideline-recommended sedation strategies is incomplete and much lower than previously suggested \[[@CR6]--[@CR10]\]. The large size, international scope, use of daily measures, and broad inclusion criteria all support the strength of the findings. Therefore, we consider the findings to be widely representative and applicable to the care of critically ill adults.

Limitations are largely related to the nature of data collection in the original ISMV studies. Across this unfunded international research collaborative, there was no resource or ability to standardize the execution of the PAD guidelines, despite the multinational, interdisciplinary nature of the original guideline. Our goal was simply to determine how this recommendation translated into actual practice change in the real world. Therefore, not all guideline recommendations were able to be considered using the available data. Likewise, assessments of patient measures were often limited to once daily monitoring, which may not accurately reflect the rapidly changing nature of critical care medicine and delirium. Dosages of medications were not considered, which would have made for a more robust analysis. Finally, quality and accuracy of delirium assessment is unknown and appears lower than expected based on previous studies. However, if delirium rates are underestimated, the findings of our multinomial regression would also likely be underestimated, suggesting that the true association of delirium with previously identified risk factors would be even stronger. Despite these limitations, this study provides considerable insight into trends in sedation practices and implementation of the 2013 PAD guidelines.

These findings highlight how critical care practice has improved and where opportunities still exist. An interprofessional team is critical for addressing all aspects of care and implementing guideline-based care, including minimizing use of sedation and performing daily SATs. The movement of guidelines and evidenced-based practice into routine clinical use requires detailed examination of patient, provider, facility, and policy factors influencing consistent implementation. Despite the strong data supporting SAT and other PAD elements, there are likely weaknesses across knowledge dissemination, resources, leadership, and programmatic quality/process improvement initiatives creating heterogeneity of practices across the world. These unique environment-specific barriers in implementation for PAD guidelines still need to be better defined. More work is needed to address how to implement these best practices. Future directions should include evaluating implementation of other aspects of the guidelines, accounting for cumulative medication doses including intermittent analgesia and sedation use, developing structured team-based approaches, and identifying methods for preventing and treating ICU delirium.

Conclusions {#Sec8}
===========

In these multicenter, international, prospective cohorts of mechanically ventilated adults, we observed substantial differences in sedation strategies between 2010 and 2016, before and after publication of 2013 PAD guidelines. In addition, practices varied widely between regions. In accordance with PAD guideline recommendations, use of benzodiazepines decreased among all regions, though benzodiazepines remained the sedative of choice in Africa, Latin America, and Asia in 2016. Despite increases in the performance of SATs, especially in the US/Canada region, SATs were performed a minority of the time. Occurrence of delirium increased slightly overall possibly due to observation bias and limited delirium monitoring.
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Additional file 1:**Table** **1:** Risk factors for daily development of delirium in 2016 cohort. (DOCX 56 kb)
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:   Bilevel positive airway pressure

BMI
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:   Continuous positive airway pressure

ICU

:   Intensive care unit
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IRB
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:   International study of mechanical ventilation

NMB

:   Neuromuscular blockage

PAD

:   Pain, agitation, and delirium
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:   Richmond agitation and sedation scale

SAPSII

:   Simplified acute physiology score
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:   Spontaneous awakening trial
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:   United States
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